Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D04USG
|
||||
Former ID |
DIB007951
|
||||
Drug Name |
MMP-13 inhibitors
|
||||
Synonyms |
MMP-13 inhibitors (arthritis); MMP-13 inhibitors (arthritis), Boehringer-Ingelheim
|
||||
Indication | Osteoarthritis [ICD9: 715; ICD10:M15-M19, M47] | Investigative | [552075] | ||
Company |
Boehringer Ingelheim Corp
|
||||
Structure |
Download2D MOL |
||||
Canonical SMILES |
c1nccc(c1)CNC(=O)c1nc(c([nH]1)c1ccc2c(c1)cc([nH]2)c1nc(<br />no1)C)C
|
||||
Target and Pathway | |||||
Target(s) | Collagenase 3 | Target Info | Inhibitor | [528284], [536172] | |
NetPath Pathway | IL1 Signaling Pathway | ||||
PANTHER Pathway | Alzheimer disease-presenilin pathway | ||||
Plasminogen activating cascade | |||||
Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
References | |||||
Ref 528284 | Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol. 2006 Jul 4;48(1):15-20. Epub 2006 Jun 21. | ||||
Ref 536172 | Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2522-7. Epub 2006 Jan 20. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.